Glioma | Epidemiology | Mature Markets Data

Publish date: March 2019

Login to access report

DRG Epidemiology's coverage of glioma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of glioma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.

DRG Epidemiology's glioma forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with glioma per year?
  • Of all people diagnosed with glioma, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of glioma over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, DRG Epidemiology forecasts 21 glioma patient populations, as follows:

  • Glioma diagnosed incident cases
  • Astrocytic glioma diagnosed incident cases
  • Oligodendroglioma diagnosed incident cases
  • Oligoastrocytoma diagnosed incident cases
  • Ependymal diagnosed incident cases
  • Diagnosed 1st line drug-treatable glioblastoma
  • … and many more (details available on request).

Note: coverage may vary by country.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
        • Diagnosed Incidence of glioma per 100,000 in 2019 and 2039
        • Relative Sizes of the Factors Contributing to the Trend in Incident cases of Glioma over the Next Ten Years
        • Analysis of Diagnosed Incident cases of Glioma Across the Countries Under Study in 2019 by Subtype
    • Epidemiology Data
    • Methods
      • Lifetime DALYs Gained
      • Diagnosed Incident Cases
      • Histology
      • Recurrent Incident Cases of Astrocytic Glioma
      • Diagnosed Prevalent Cases of Astrocytic Glioma
      • Drug-Treatable and Drug-Treated Populations
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Nishant Kumar, MPH

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.